Volume 21, Number 6—June 2015
CME ACTIVITY - Research
Estimated Deaths and Illnesses Averted During Fungal Meningitis Outbreak Associated with Contaminated Steroid Injections, United States, 2012–2013
Table 3
Characteristic |
Diagnosis date on or before October 4, n = 82 |
Diagnosis date after October 4, n = 307 |
p value |
CSF parameters* | |||
Median leukocyte count, cells/μL | 1,064 | 29 | <0.0001 |
Median total protein, g/dL Median glucose, mg/dL | 117 38 | 71 55 | <0.0001 <0.0001 |
Median no. of symptoms | 5 | 4 | <0.0001 |
Antifungal treatment within 48 h of diagnosis | 20 (59%)† | 173 (84%)† | 0.0006 |
Death within 60 d of diagnosis | 23 (28%)‡ | 17 (6%)‡ | <0.0001 |
Laboratory-confirmed cases only, n = 110 | 33 | 77 | |
Death within 60 d of diagnosis | 13 (39%)§ | 6 (8%)§ | <0.0001 |
*CSF, cerebrospinal fluid.
†The denominators used for percentages represent the number of case-patients for whom data on antifungal treatment was available (34 and 206, respectively) for each diagnosis period.
‡The denominators used for percentages are the total number of case-patients for each diagnosis period.
§The denominators used were the total laboratory-confirmed cases for each diagnosis period.
Page created: October 06, 2015
Page updated: October 06, 2015
Page reviewed: October 06, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.